Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 10 PAGES: 38

More Info
									                 Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT
                                        Analysis Review
        Reference Code: GDPH58638FSA                                                                                          Publication Date: MAY 2012

          4939 Directors Place                               Phone              +1 858 6526500                  Revenue          7.3 (million USD)
          San Diego, CA                                      Fax                +1 858 6250760                  Net Profit       -86.58 (million USD)
          92121                                              Website            www.ardeabio.com                Employees        107
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           RDEA [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Ardea Biosciences, Inc. (Ardea) is a biotechnology company. It focuses on the development of small molecules as a novel
       therapeutics for the treatment of gout and cancer. The product portfolio of the company includes three pipeline products, namely,
       Lesinurad (RDEA 594), RDEA 3170 and Bay 86-966 (RDEA 119). Lesinurad and RDEA 3170 are currently in Phase-III and
       Phase-I clinical trials respectively, being developed as a treatment for gout. Bay 86-966 is a Phase-II clinical trials stages
       respectively being developed as a treatment for cancer. The company also has a subsidiary named Ardea Biosciences Limited in
       England. Ardea is headquartered in San Diego, California, the US.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Ardea Biosciences, Inc., SWOT Analysis
         Barry D. Quart, PharmD              Chief Executive Officer                  Strengths                              Weaknesses
         Henry J. Fuchs                      Director
                                                                                      Focused Research and                   Weak Profitability Margin
         Kevin C. Tang                       Director                                 Development
                                                                                                                             Involvement in Legal
         John Poyhonen                       Director
                                                                                      Patent Base                            Proceedings
         Craig Johnson                       Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Synergy through AstraZeneca            Regulatory Environment
         Ardea Biosciences, Inc.                                                      PLC
                                                                                                                             Uncertain R&D Outcomes
        Share Price (USD) as on 04-                                    31.70          Growing Oncology Treatment
        May-2012                                                                      Market
        EPS (USD)                                                       -3.26
        Market Cap (million USD)                                       1,165         Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Enterprise Value (million USD)                                 1,161
        Shares Outstanding (million)                                       37
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 09, 2012         Ardea Biosciences Reports Revenue Of $1.7m
                                                                                                           In Q4 2011
                                                                                      Nov 04, 2011         Ardea Biosciences Reports Revenue Of $1.7m
                                                                                                           In Q3 2011
                                                                                      Aug 05, 2011         Ardea Biosciences Reports Total Revenue Of
                                                                                                           $2.2m For Q2 2011
                                                                                      May 09, 2011         Ardea Biosciences Reports Net Loss Of
                                                                                                           $15.2m For Q1 2011
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT                                                                  Reference Code: GDPH58638FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Ardea Biosciences, Inc. - Key Facts ................................................................................................................................................... 5
       Ardea Biosciences, Inc. - Key Employees .......................................................................................................................................... 6
       Ardea Biosciences, Inc. - Key Employee Biographies ........................................................................................................................ 7
       Ardea Biosciences, Inc. - Major Products and Services ..................................................................................................................... 8
       Ardea Biosciences, Inc. - Pharmaceutical Pipeline Products Data ..................................................................................................... 9
          Ardea Biosciences, Inc., Pipeline Products by Therapy Area ......................................................................................................... 9
          Ardea Biosciences, Inc., Pipeline Products by Development Phase............................................................................................. 10
       Ardea Biosciences, Inc. - History ...................................................................................................................................................... 12
       Ardea Biosciences, Inc. - Company Statement ................................................................................................................................ 13
       Ardea Biosciences, Inc. - Locations And Subsidiaries ...................................................................................................................... 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Ardea Biosciences, Inc. - Business Description ............................................................................................................................... 16
       Ardea Biosciences, Inc. - SWOT Analysis ........................................................................................................................................ 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Ardea Biosciences, Inc. - Strengths .............................................................................................................................................. 17
             Strength - Focused Research and Development ...................................................................................................................... 17
             Strength - Patent Base .............................................................................................................................................................. 17
             Strength - Global Agreement with Bayer HealthCare ................................................................................................................ 17
          Ardea Biosciences, Inc. - Weaknesses ......................................................................................................................................... 17
             Weakness - Weak Profitability Margin ....................................................................................................................................... 17
             Weakness - Involvement in Legal Proceedings......................................................................................................................... 18
          Ardea Biosciences, Inc. - Opportunities ........................................................................................................................................ 18
             Opportunity - Synergy through AstraZeneca PLC ..................................................................................................................... 18
             Opportunity - Growing Oncology Treatment Market .................................................................................................................. 18
             Opportunity - Targeting the Treatments for Gout ...................................................................................................................... 18
          Ardea Biosciences, Inc. - Threats ................................................................................................................................................. 19
             Threat - Regulatory Environment .............................................................................................................................................. 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
             Threat - Dependence on Third Party Contractors ..................................................................................................................... 19
             Threat - Competitive Pressures ................................................................................................................................................. 19
       Ardea Biosciences, Inc. - Key Competitors ...................................................................................................................................... 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27


Ardea Biosciences, Inc. (RDEA) - Financial and Strategic SWOT                                                                                                  Reference Code: GDPH58638FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, 
								
To top